> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Teva Spurns FDA’s Beta-Lactam Drug Recommendation
- URL: https://www.fdaweb.com/teva-spurns-fdas-beta-lactam-drug-recommendation/
- Published: 2024-05-28T12:00:00.000Z
- Updated: 2026-09-14T14:31:53.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5157066

Teva says an FDA recommendation for a unique manufacturing treatment for the cholesterol drug ezetimibe (Zetia) is inconsistent with the agency’s and other health authorities’ past regulatory treatment of the product and is “unwarranted.” The company’s analysis is in a comment [letter](ttps://downloads.regulations.gov/FDA-2011-D-0104-0027/attachment%5F1.pdf) for the FDA docket on a draft guidance for a CGMP (current good manufacturing practice) framework to prevent cross-contamination in non-penicillin beta-lactam drugs.

The company says that because ezetimibe is not an antibiotic, it does not present an allergic risk like non-penicillin antibacterial beta-lactams. Thus, it says, standard risk assessment approaches using health-based exposure limits are appropriate for protecting patients from potential cross-contamination with ezetimibe.

“We ask that FDA clarify in final guidance that manufacturing of ezetimibe is not required to be completely and comprehensively separated from non-beta-lactam drug products,” Teva concludes. “In addition, because ezetimibe does not present a beta-lactam allergy risk, patient health can be protected against cross-contamination risk by using health-based exposure limits and risk assessment and there is no need for manufacturing facilities dedicated to ezetimibe manufacturing. If FDA is aware of data showing cross-reactivity risk for ezetimibe, we welcome publication of such data in an updated draft guidance for public review and comment.”